SET KD was furthermore shown to enhance PP2A activity; to inhibit mTORC1/p70S6K, β-catenin, and NFκB signaling; and to suppress the tumorigenic characteristics of a canine mammary tumor cell line. This evidence concerns the gene SET and breast cancer.